CY1119490T1 - Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων - Google Patents

Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων

Info

Publication number
CY1119490T1
CY1119490T1 CY20171101108T CY171101108T CY1119490T1 CY 1119490 T1 CY1119490 T1 CY 1119490T1 CY 20171101108 T CY20171101108 T CY 20171101108T CY 171101108 T CY171101108 T CY 171101108T CY 1119490 T1 CY1119490 T1 CY 1119490T1
Authority
CY
Cyprus
Prior art keywords
pyrazolopyrolidine
products
patient treatment
present
provides
Prior art date
Application number
CY20171101108T
Other languages
English (en)
Inventor
Jutta Blank
Vincent Bordas
Simona Cotesta
Vito Guagnano
Heinrich Rueeger
Andrea Vaupel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1119490T1 publication Critical patent/CY1119490T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Η παρούσα εφεύρεση παρέχει μια ένωση του χημικού τύπου (I) ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, μια μέθοδο για την παρασκευή των ενώσεων της εφεύρεσης και τις θεραπευτικές τους χρήσεις. Η παρούσα εφεύρεση επιπλέον παρέχει έναν συνδυασμό φαρμακολογικώς δραστικών παραγόντων και μια φαρμακευτική σύνθεση.
CY20171101108T 2013-05-27 2017-10-25 Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων CY1119490T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13169364 2013-05-27
EP13177673 2013-07-23
PCT/IB2014/061717 WO2014191896A1 (en) 2013-05-27 2014-05-26 Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP14731799.4A EP3004110B1 (en) 2013-05-27 2014-05-26 Pyrazolopyrrolidine derivatives and their use in the treatment of disease

Publications (1)

Publication Number Publication Date
CY1119490T1 true CY1119490T1 (el) 2018-03-07

Family

ID=50979827

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101108T CY1119490T1 (el) 2013-05-27 2017-10-25 Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων

Country Status (37)

Country Link
US (2) US8975417B2 (el)
EP (1) EP3004110B1 (el)
JP (1) JP6181862B2 (el)
KR (1) KR20160012196A (el)
CN (1) CN105408335B (el)
AU (1) AU2014272776C1 (el)
BR (1) BR112015029512A8 (el)
CA (1) CA2913223A1 (el)
CL (1) CL2015003395A1 (el)
CR (1) CR20150628A (el)
CU (1) CU24350B1 (el)
CY (1) CY1119490T1 (el)
DK (1) DK3004110T3 (el)
EA (1) EA029515B1 (el)
EC (1) ECSP15053445A (el)
ES (1) ES2651843T3 (el)
HK (1) HK1216251A1 (el)
HR (1) HRP20171613T1 (el)
HU (1) HUE036674T2 (el)
IL (1) IL242610A0 (el)
LT (1) LT3004110T (el)
ME (1) ME02906B (el)
MX (1) MX364205B (el)
NO (1) NO3004110T3 (el)
PE (1) PE20160005A1 (el)
PH (2) PH12015502628B1 (el)
PL (1) PL3004110T3 (el)
PT (1) PT3004110T (el)
RS (1) RS56522B1 (el)
SG (1) SG11201509474SA (el)
SI (1) SI3004110T1 (el)
SV (1) SV2015005115A (el)
TN (1) TN2015000505A1 (el)
UA (1) UA116017C2 (el)
UY (1) UY35586A (el)
WO (1) WO2014191896A1 (el)
ZA (1) ZA201508259B (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
PE20151990A1 (es) 2013-03-15 2016-01-13 Incyte Corp Heterociclos triciclicos como inhibidores de la proteina bet
EA028175B1 (ru) * 2013-05-28 2017-10-31 Новартис Аг Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
EP3674300B1 (en) 2013-06-21 2022-10-12 Zenith Epigenetics Ltd. Novel bicyclic bromodomain inhibitors
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
KR20160038008A (ko) 2013-07-31 2016-04-06 제니쓰 에피제네틱스 코포레이션 브로모도메인 억제제로서 신규 퀴나졸리논
CA2927567C (en) 2013-10-18 2022-04-26 Celgene Quanticel Research, Inc. Bromodomain inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CR20160542A (es) 2014-04-23 2017-04-25 Incyte Corp 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
MX2018001751A (es) 2015-08-11 2018-08-01 Neomed Inst Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.
WO2017024412A1 (en) 2015-08-12 2017-02-16 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
WO2017127930A1 (en) * 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
CN109153647A (zh) 2016-02-15 2019-01-04 分子医学研究中心责任有限公司 用于治疗癌症的taf1抑制剂
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
US11298354B2 (en) * 2016-06-09 2022-04-12 Dana-Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors
CA3220957A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
AU2017359288A1 (en) 2016-11-14 2019-05-30 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
WO2021009068A1 (en) * 2019-07-12 2021-01-21 Scenic Immunology B.V. N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme
WO2021065980A1 (ja) 2019-09-30 2021-04-08 協和キリン株式会社 Ｂｅｔ分解剤
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022155859A1 (en) * 2021-01-21 2022-07-28 Beijing Tiantan Hospital Modulators of fpr1 and methods of using the same
WO2023012044A1 (en) 2021-08-02 2023-02-09 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023110871A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2023233130A1 (en) 2022-05-30 2023-12-07 AdoRx Therapeutics Limited Cd73 inhibitor compounds
WO2024068947A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
NZ524475A (en) 2000-08-10 2004-11-26 Pharmacia Italia S Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ES2289116T3 (es) * 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
DE60225719T2 (de) 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
WO2003095625A2 (en) 2002-05-13 2003-11-20 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
ES2314660T3 (es) 2004-05-18 2009-03-16 F. Hoffmann-La Roche Ag Nuevas cis-imidazolinas.
US20060069085A1 (en) 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
CA2589830A1 (en) 2005-01-05 2006-07-13 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7968583B2 (en) 2005-12-12 2011-06-28 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
WO2007096334A1 (en) 2006-02-24 2007-08-30 Pfizer Italia Srl Pyrrolopyrrolones active as kinase inhibitors
WO2008034039A2 (en) 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
CA2682473A1 (en) 2007-03-30 2008-10-09 Shionogi & Co., Ltd. Novel pyrrolinone derivative and pharmaceutical composition comprising the same
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
WO2010035727A1 (ja) 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2010141738A2 (en) 2009-06-03 2010-12-09 President And Fellows Of Harvard College Compositions and method for inhibiting tumor growth
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
GB2492950A (en) 2011-07-11 2013-01-23 Cambridge Consultants Measuring a luminescent property of a sample using a dual-modulated excitation beam
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds

Also Published As

Publication number Publication date
SG11201509474SA (en) 2015-12-30
PH12015502628A1 (en) 2016-03-07
BR112015029512A2 (pt) 2017-07-25
RS56522B1 (sr) 2018-02-28
KR20160012196A (ko) 2016-02-02
WO2014191896A1 (en) 2014-12-04
BR112015029512A8 (pt) 2019-12-17
SI3004110T1 (sl) 2017-11-30
SV2015005115A (es) 2018-04-04
US8975417B2 (en) 2015-03-10
CN105408335B (zh) 2017-11-17
IL242610A0 (en) 2016-02-01
MX364205B (es) 2019-04-16
LT3004110T (lt) 2017-11-10
ME02906B (me) 2018-04-20
EP3004110A1 (en) 2016-04-13
UY35586A (es) 2014-12-31
ECSP15053445A (es) 2017-10-31
CL2015003395A1 (es) 2016-05-20
US20140349990A1 (en) 2014-11-27
PE20160005A1 (es) 2016-01-21
HRP20171613T1 (hr) 2017-12-01
CU20150163A7 (es) 2016-05-30
CU24350B1 (es) 2018-06-05
EA201592250A1 (ru) 2016-05-31
AU2014272776B2 (en) 2016-11-10
PL3004110T3 (pl) 2017-12-29
MX2015016416A (es) 2016-03-03
AU2014272776A1 (en) 2015-12-03
HK1216251A1 (zh) 2016-10-28
UA116017C2 (uk) 2018-01-25
CR20150628A (es) 2016-01-29
PH12018501807A1 (en) 2019-03-25
CN105408335A (zh) 2016-03-16
HUE036674T2 (hu) 2018-07-30
PH12015502628B1 (en) 2016-03-07
DK3004110T3 (da) 2017-11-06
AU2014272776C1 (en) 2017-06-01
EP3004110B1 (en) 2017-07-26
US20160095843A1 (en) 2016-04-07
PT3004110T (pt) 2017-11-08
JP2016520117A (ja) 2016-07-11
JP6181862B2 (ja) 2017-08-16
CA2913223A1 (en) 2014-12-04
ZA201508259B (en) 2017-01-25
TN2015000505A1 (en) 2017-04-06
ES2651843T3 (es) 2018-01-30
NO3004110T3 (el) 2017-12-23
EA029515B1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201692298A1 (ru) Производные карбоксамидов
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
MX2019004484A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
EA201991008A1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии